A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

<p>Abstract</p> <p>Background</p> <p>Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the <it>von Hippel-Lindau </it>(<it>VHL</it&...

Full description

Bibliographic Details
Main Authors: Steinberg Seth M, Linehan W Marston, Herrin Vincent E, Gause Barry, Toubaji Antoun, Ibrahim Ramy, Ashtar Ed, Rahma Osama E, Grollman Frank, Grimes George, Bernstein Sarah A, Berzofsky Jay A, Khleif Samir N
Format: Article
Language:English
Published: BMC 2010-01-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/8

Internet

http://www.translational-medicine.com/content/8/1/8

Similar Items